Mechanism of Action
Y4 Receptor Selectivity
PP has highest affinity for Y4 receptors (Gi-coupled) expressed in the brainstem area postrema, hypothalamus, gut, and pancreas. Y4 activation in the area postrema reduces vagal tone to the GI tract, slowing gastric emptying and reducing appetite signals to the hypothalamus. This receptor selectivity distinguishes PP's anorectic mechanism from NPY (Y1/Y5 agonist, orexigenic) and PYY3-36 (Y2 agonist, anorectic), illustrating how the NPY peptide family achieves opposing metabolic effects through different receptor subtypes.
Pancreatic and GI Regulation
PP inhibits pancreatic exocrine enzyme and bicarbonate secretion, acting as a counterregulatory brake after the cholecystokinin-driven digestive stimulation. PP also relaxes the gallbladder and inhibits intestinal motility. These effects slow post-absorptive nutrient processing and contribute to the satiety and reduced refeeding observed after PP infusion.
Research Summary
Obesity and Food Intake
Phase 1/2IV PP infusion (0.5-2 pmol/kg/min) in lean subjects reduces food intake at a subsequent meal by 21-25% and lowers plasma ghrelin/" class="wiki-internal-link">ghrelin. In obese subjects, the response is attenuated, suggesting PP resistance. Prader-Willi syndrome (characterized by hyperphagia and obesity) shows significantly reduced PP responses to meals; PP infusion partially normalizes food intake in these patients. Phase 1 trials of longer-acting PP analogs are underway.
Prader-Willi Syndrome
Active ResearchPrader-Willi syndrome patients have blunted PP secretion and near-absent Y4 signaling, potentially contributing to their insatiable hunger. Multiple trials of PP or Y4 agonist administration have been conducted. Octreotide (reduces insulin, may increase PP) showed modest appetite reduction in small PWS trials. Y4 receptor agonist development specifically targeting the PWS satiety deficit is an active area.
Calculate your Pancreatic Polypeptide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite research (human) | 0.5-2 pmol/kg/min IV infusion for 90-120 minutes before meal | Per research session | Intravenous infusion |
Research-grade PP only. No approved therapeutic form. Short half-life makes IV infusion necessary for sustained effects; analog development aims to solve this limitation.
Interactions
Safety Profile
IV PP infusion at research doses is well tolerated. Mild nausea at higher infusion rates. Reduction of pancreatic secretion is the intended pharmacological effect and does not cause clinical deficiency at acute research doses. No significant cardiovascular, hepatic, or renal adverse effects identified. Long-term administration has not been studied in humans. Endogenous PP deficiency in obesity and PWS suggests that PP replacement therapy would be physiologically appropriate, not pharmacologically excessive.
References
- [1]Batterham RL, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88(8):3989-3992.
- [2]Ueno N, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology. 1999;117(6):1427-1432.